NorthWest Biotherapeutics Inc (NWBO)

[hope4patients]

Published today (4-15-2019) out of Johns Hopkins:

"In May of 2018, Liau et al. published interim results on the first Phase III clinical trial of autologous tumor lysate pulsed dendritic cell vaccine (DCVax-L) in newly diagnosed GBM. Patients underwent standard surgery and chemoradiation, after which they were randomized 2:1 to receive either temozolomide plus DCVax-L or temozolomide and placebo. Following recurrence, patients were given the option of receiving DCVax-L; therefore, >90% of patients with the intent to treat population received DCVax-L. The median survival for the intent to treat population was 23.1 months from surgery with 223 patients who are >30 months past surgery and 182 patients who are >62 months past surgery. Only 21% of patients had grade 3 or 4 adverse events. The results of this Phase III clinical trial show promising feasibility of integrating DCV into standard therapy and suggests a survival benefit [214]."

Source: https://www.mdpi.com/2072-6694/11/4/537/htm